Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre- vs. postoperative thromboprophylaxis for liver resection
2019-002323-15Phase 4Active
- Sponsor
- Helsinki University Hospital
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of dalteparin and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Venous thromboembolisms within 30 days. Started Mar 2021; status: active.
02
Drugs
dalteparinenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2019-002323-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002323-15.